AR099510A1 - Régimen de dosaje del compuesto fgf-18 - Google Patents

Régimen de dosaje del compuesto fgf-18

Info

Publication number
AR099510A1
AR099510A1 ARP150100508A ARP150100508A AR099510A1 AR 099510 A1 AR099510 A1 AR 099510A1 AR P150100508 A ARP150100508 A AR P150100508A AR P150100508 A ARP150100508 A AR P150100508A AR 099510 A1 AR099510 A1 AR 099510A1
Authority
AR
Argentina
Prior art keywords
fgf
compound
use according
mcg
administered
Prior art date
Application number
ARP150100508A
Other languages
English (en)
Inventor
H Ladel Christoph
Guehring Hans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR099510A1 publication Critical patent/AR099510A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Reivindicación 1: Un compuesto FGF-18 para uso en el tratamiento de una enfermedad del cartílago donde el compuesto FGF-18 será administrado al menos dos veces por ciclo de tratamiento, y dichas administraciones están separadas una de la otra por aproximadamente 2 semanas. Reivindicación 4: El compuesto FGF-18 para uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde los ciclos de tratamiento se repiten luego de 2, 3, 4, 5 ó 6 meses. Reivindicación 6: El compuesto FGF-18 para uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde el compuesto FGF-18 será administrado intra articularmente. Reivindicación 7: El compuesto FGF-18 para uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde el compuesto FGF-18 será administrado en una dosis de 3 - 300 mcg, preferentemente 10 - 200 mcg, mas preferentemente 30 - 150 mcg o incluso más preferentemente 30 - 120 mcg por administración intra articular única. Reivindicación 9: El compuesto FGF-18 para uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde el cartílago es cartílago articular. Reivindicación 12: El compuesto FGF-18 para uso de acuerdo con cualquiera de las reivindicaciones precedentes, donde el compuesto FGF-18 es seleccionado del grupo que consiste en: a) un polipéptido que comprende o consiste en la forma FGF-18 madura humana que comprende residuos 28 - 207 de la secuencia SEQ ID Nº 1, o b) un polipéptido que comprende o consiste en la secuencia SEQ ID Nº 2.
ARP150100508A 2014-02-20 2015-02-20 Régimen de dosaje del compuesto fgf-18 AR099510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20

Publications (1)

Publication Number Publication Date
AR099510A1 true AR099510A1 (es) 2016-07-27

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150100507A AR099558A1 (es) 2014-02-20 2015-02-20 Régimen de dosaje del compuesto fgf-18
ARP150100508A AR099510A1 (es) 2014-02-20 2015-02-20 Régimen de dosaje del compuesto fgf-18

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150100507A AR099558A1 (es) 2014-02-20 2015-02-20 Régimen de dosaje del compuesto fgf-18

Country Status (25)

Country Link
US (2) US9889179B2 (es)
EP (2) EP3119417B1 (es)
JP (2) JP6431083B2 (es)
KR (2) KR102410988B1 (es)
CN (2) CN106456713A (es)
AR (2) AR099558A1 (es)
AU (2) AU2015220773B2 (es)
BR (2) BR112016018696A2 (es)
CA (2) CA2938793A1 (es)
DK (2) DK3107559T3 (es)
ES (2) ES2688551T3 (es)
HR (2) HRP20181572T1 (es)
HU (1) HUE040350T2 (es)
IL (2) IL247084B (es)
LT (2) LT3107559T (es)
MX (2) MX2016010872A (es)
NZ (2) NZ723148A (es)
PL (2) PL3119417T3 (es)
PT (2) PT3119417T (es)
RS (2) RS57709B1 (es)
RU (2) RU2691946C2 (es)
SG (2) SG11201606505UA (es)
SI (2) SI3119417T1 (es)
WO (2) WO2015124731A1 (es)
ZA (2) ZA201605548B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124739A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Implant comprising fgf-18
SG11201606505UA (en) 2014-02-20 2016-09-29 Merck Patent Gmbh Fgf-18 compound dosing regimen
SI3419625T1 (sl) 2016-02-22 2021-08-31 Novartis Ag Postopki za uporabo agonistov FXR
CN111164429A (zh) * 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物
WO2020161341A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
EP1978997A1 (en) * 2005-12-22 2008-10-15 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
ES2392883T3 (es) * 2006-08-25 2012-12-14 Ares Trading S.A. Tratamiento de trastornos de cartílagos con FGF-18
JP5815206B2 (ja) * 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
WO2015124739A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Implant comprising fgf-18
SG11201606505UA (en) 2014-02-20 2016-09-29 Merck Patent Gmbh Fgf-18 compound dosing regimen

Also Published As

Publication number Publication date
RU2700582C2 (ru) 2019-09-18
PL3119417T3 (pl) 2019-01-31
ES2688551T3 (es) 2018-11-05
HRP20181570T1 (hr) 2018-11-30
LT3107559T (lt) 2018-10-25
ES2689071T3 (es) 2018-11-08
CN106456713A (zh) 2017-02-22
IL247083A0 (en) 2016-09-29
JP2017512194A (ja) 2017-05-18
WO2015124731A1 (en) 2015-08-27
MX2016010872A (es) 2016-11-17
RS57853B1 (sr) 2018-12-31
RU2016137289A3 (es) 2018-10-19
EP3107559A1 (en) 2016-12-28
JP2017507142A (ja) 2017-03-16
US20170072017A1 (en) 2017-03-16
RU2016137292A3 (es) 2018-09-17
AU2015220777B2 (en) 2020-10-22
JP6431082B2 (ja) 2018-11-28
EP3119417A1 (en) 2017-01-25
SI3119417T1 (sl) 2018-11-30
LT3119417T (lt) 2018-10-25
CA2938793A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
AU2015220773A1 (en) 2016-09-01
RU2016137292A (ru) 2018-03-21
EP3119417B1 (en) 2018-07-11
ZA201605548B (en) 2018-12-19
KR20160116001A (ko) 2016-10-06
AU2015220777A1 (en) 2016-09-01
CA2938791A1 (en) 2015-08-27
SG11201606505UA (en) 2016-09-29
IL247084A0 (en) 2016-09-29
IL247083B (en) 2019-09-26
BR112016018696A2 (pt) 2017-10-17
EP3107559B1 (en) 2018-07-11
BR112016018685A2 (pt) 2017-10-17
ZA201605547B (en) 2019-09-25
US9889179B2 (en) 2018-02-13
HRP20181572T1 (hr) 2018-11-30
JP6431083B2 (ja) 2018-11-28
RS57709B1 (sr) 2018-12-31
SI3107559T1 (sl) 2018-11-30
PT3119417T (pt) 2018-10-31
WO2015124727A1 (en) 2015-08-27
DK3107559T3 (en) 2018-10-15
US9724388B2 (en) 2017-08-08
AR099558A1 (es) 2016-08-03
NZ723148A (en) 2022-08-26
IL247084B (en) 2019-09-26
MX2016010871A (es) 2016-11-17
US20170056474A1 (en) 2017-03-02
KR20160116000A (ko) 2016-10-06
KR102410988B1 (ko) 2022-06-17
NZ723139A (en) 2022-12-23
AU2015220773B2 (en) 2020-10-08
PL3107559T3 (pl) 2019-01-31
SG11201606502YA (en) 2016-09-29
DK3119417T3 (en) 2018-10-22
KR102410986B1 (ko) 2022-06-17
CN106232622A (zh) 2016-12-14
PT3107559T (pt) 2018-10-31
RU2016137289A (ru) 2018-03-21
HUE040350T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
AR099510A1 (es) Régimen de dosaje del compuesto fgf-18
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
DOP2019000201A (es) Compuestos inhibidores del vih
HRP20210250T1 (hr) Učinkovita i djelotvorna kontrola serumskog fosfata za optimalno stvaranje kostiju
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
ECSP18073245A (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
EA201591701A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
AR116451A1 (es) Administración oral de análogos del péptido glp-1
MX2018000240A (es) Metodos para tratar el vhc.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
CL2018001881A1 (es) Compuestos y composiciones para el tratamiento de la criptoporidiosis
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
JP2017507142A5 (es)
JP2017512194A5 (es)
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
AR108790A1 (es) Métodos y composiciones para el tratamiento de la enfermedad celíaca, de la sensibilidad al gluten no celíaca y de la enfermedad celíaca refractaria
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w

Legal Events

Date Code Title Description
FB Suspension of granting procedure